Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 8/12/2019
SIETES contiene 92850 citas

 
 
 1 a 20 de 435 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
2. Cita con resumen
Tracy DK. Gabapentinoids linked to new risks, including suicidal behaviour. BMJ 2019;365:12 de junio. [Ref.ID 103153]
3.Enlace a cita original Cita con resumen
Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med 2019;179:mayo. [Ref.ID 103073]
4. Cita con resumen
Thielking M. Federal trial over fentanyl bribes gets underway. STAT Morning Rounds 2019:2. [Ref.ID 103007]
5. Cita con resumen
Montastruc F, Loo SY, Renoux C. Trends in first gabapentin and pregabalin prescriptions in primary care in the United Kingdom, 1993-2017. JAMA 2018;320:27 de noviembre. [Ref.ID 102915]
6.Enlace a cita originalTiene citas relacionadas Cita con resumen
Ray WA, Stein CM, Murray KT, Fuchs DC, Patrick SW, Daugherty J, Hall K, Cooper WO. Association of antipsychotic treatment with risk of unexpected death among children and youths. JAMA Psychiatry 2018:12 de diciembre. [Ref.ID 102895]
7.Enlace a cita original Cita con resumen
Asensio C, Escoda N, Sabaté M, Carbonell P, López P, Laporte JR. Prevalence of use of antipsychotic drugs in the elderly in Catalonia. Eur J Clin Pharmacol 2018;74:septiembre. [Ref.ID 102828]
8.Enlace a cita original Cita con resumen
Cohen LS, Góez-Mogollón L, Sosinsky AZ, Savella GM, Viguera AC, Chitayat D, Hernández-Díaz S, Freeman MP. Risk of major malformations in infants following first-trimester exposure to quetiapine. Am J Psychiatry 2018:16 de agosto. [Ref.ID 102798]
9.Enlace a cita originalTiene citas relacionadas Cita con resumen
Wallach JD, Ross JS. Gabapentin approvals, off-label use, and lessons for postmarketing evaluation efforts. JAMA 2018;319:27 de febrero. [Ref.ID 102781]
10.Enlace a cita originalTiene citas relacionadas Cita con resumen
Moore A, Derry S, Wiffen P. Gabapentin for chronic neuropathic pain. JAMA 2018;319:27 de febrero. [Ref.ID 102777]
11. Cita con resumen
Thielking M. FDA cracks down on ‘vaginal rejuvenation’ devices, citing potential for serious harm. STAT Daily Recap 2018:30 de julio. [Ref.ID 102728]
13.Enlace a cita original Cita con resumen
Park Y, Bateman BT, Kim DH, Hernandez-Diaz S, Patorno E, Glynn RJ, Mogun H, Hyubrechts KF. Use of haloperidol versus atypical antipsychotics and risk of in-hospital death in patients with acute myocardial infarction: cohort study. BMJ 2018;360:28 de marzo. [Ref.ID 102642]
14.Enlace a cita original Cita con resumen
Johansen ME. Gabapentinoid use in the United States 2002 trhrough 2015. JAMA Intern Med 2018;178:febrero. [Ref.ID 102530]
16. Cita con resumen
Schröder C, Dörcks M, Kollhorst B, Blenk T, Dittmann RW, Garbe E, Riedel O. Extent and risks of antidepressant off-label use in children and adolescents in Germany between 2004 and 2011. Pharmacoepidemiol Drug Saf 2017;26:1395-402. [Ref.ID 102134]
17.Tiene citas relacionadas Cita con resumen
Makary MA, Overton HN, Wang P. Overprescribing is major contributor to opioid crisis. BMJ 2017;359:j4792. [Ref.ID 102106]
18. Cita con resumen
Gjerden P, Bramness JG, Tvete IF, Slordal L. The antipsychotic agent quetiapine is increasingly not used as such: dispensed prescriptions in Norway 2004–2015. Eur J Clin Pharmacol 2017;73:1173-9. [Ref.ID 102025]
19. Cita con resumen
Jobski K, Schmedt N, Kollhorst B, Krappweis J, Schink T, Garbe E. Characteristics and drug use patterns of older antidepressant initiators in Germany. Eur J Clin Pharmacol 2017;73:105-13. [Ref.ID 101939]
20. Cita con resumen
Thomas K. Celgene to pay $280 Million to settle fraud suit over cancer drugs. N Y Times (Print) 2017:1. [Ref.ID 101924]
Seleccionar todas
 
 1 a 20 de 435 siguiente >>